Goodbye PCOS: The World's Most Common Hormonal Disorder in Women Has a New Name — PMOS

For nearly a century, one in eight women on the planet has lived with a diagnosis named after something most of them do not have. The 'cysts' in polycystic ovary syndrome are not cysts at all — they are immature follicles, perfectly ordinary, that simply failed to be released. On Tuesday, at the European Congress of Endocrinology in Prague, the Australian endocrinologist Helena Teede stood up and announced that the name was finally being retired. From now on, the condition will be called polyendocrine metabolic ovarian syndrome — PMOS.

The change is the result of a three-year, multi-step global consensus published in The Lancet and led by the International PCOS Network, with input from more than a hundred clinicians, researchers and patient advocates across thirty-one countries. Its argument is simple. The old name was diagnostically misleading, it was emotionally distressing for the patients who carried it, and — most damaging of all — it concealed the fact that PMOS is not a gynaecological problem with metabolic side effects, but a whole-body endocrine disorder that happens to involve the ovaries.

That distinction is not academic. Up to seventy per cent of women with the condition go undiagnosed, in part because clinicians and patients alike have been trained to look for ovarian cysts on a scan. Women without the cystic appearance — and there are many — are routinely told they do not have it, even when they have every other feature: insulin resistance, elevated androgens, irregular cycles, the cluster of cardiometabolic risks that drives long-term harm. The new name forces the diagnostic conversation back where it belongs: hormones and metabolism first, ovaries second.

PMOS is the leading cause of infertility in women of reproductive age and is associated with a sharply elevated lifetime risk of type 2 diabetes, cardiovascular disease, endometrial cancer, sleep apnoea and clinical depression. It costs health systems an estimated fifteen billion dollars a year in the United States alone. And yet research funding for it remains a fraction of what comparable chronic conditions attract — a gap the consensus authors argue is itself a downstream consequence of a name that made the disorder sound smaller than it is.

Patient groups have responded with a mixture of relief and exhaustion. The acronym is uglier; the recognition is overdue. 'For twenty years I have had to explain that I do not have cysts,' one British advocate told the BBC. 'Now I will have to explain a longer word. I will take that trade.' Clinical guidelines, ICD codes and electronic medical records will be updated through 2026 and 2027; the old term will continue to appear, in brackets, for the foreseeable future.

What the rename does not change is the underlying biology, the available treatments, or the fact that most women still wait years for a diagnosis. What it does change is the story the diagnosis tells — and, perhaps, the seriousness with which the rest of medicine is now obliged to take it.